RBC Capital lowers KKR stock price target to $128 on valuation

RBC Capital cut its price target on KKR to $128 from $132 but kept an Outperform rating, citing an attractive valuation and a fundraising cycle that could support fee-based compensation and fee-related earnings through 2027. KKR also reported Q1 2026 adjusted net income of $1.39 per share, above the $1.34 consensus, and revenue of $2.35 billion versus $2.24 billion expected. Overall tone is constructive despite the modest target cut.

Analysis

KKR is being rerated less on current earnings and more on the durability of its fundraising machine, which matters because private-markets platforms typically re-rate before fee growth actually shows up in reported numbers. The key second-order effect is that a multi-year fundraising cycle can compress the perceived cyclicality of earnings: recurring management fees become a larger share of the mix, reducing dependency on exits just as capital-markets activity remains uneven. That supports a higher multiple versus more transaction-sensitive financials, especially if public-market volatility keeps clients leaning into private credit and drawdown strategies.

The competitive winner is likely not just KKR itself but the whole alternative-asset complex with similar exposure to evergreen capital and retail/private wealth channels. If KKR can keep gathering at pace through 2027, that implies continuing share gains from smaller managers that are more exposed to performance fees and slower fundraising platforms; the losers are levered public-market asset managers whose AUM is more sensitive to beta and redemptions. The market may also be underestimating how persistent fee-related earnings can cushion any slowdown in realizations, which reduces downside in a choppy macro backdrop.

The main risk is timing: fundraising strength is a long-dated thesis, but valuation can de-rate quickly if credit spreads widen, mark-to-market losses hit flagship funds, or fundraising conversion slips even one cycle. A 15-20% pullback in the stock would not necessarily invalidate the thesis, but it would likely indicate the market is discounting slower deployment or weaker exit activity. Conversely, the move is probably underdone if the company keeps compounding fee-bearing capital and the next few quarters confirm that earnings quality is shifting toward annuity-like revenue.

The contrarian view is that the market may already be paying for too much of the 2027 story, especially given the stock still trades like a quality compounder rather than a cyclical financial. If fundraising momentum decelerates or private-asset net asset values come under pressure, the multiple could compress before the earnings uplift arrives. In that scenario, the right trade is not to fight the franchise, but to distinguish between platform quality and duration risk in the nearer-term setup.

Key Decisions for Investors

• Stay long KKR on a 6-12 month horizon, but use weakness toward a 10-15% drawdown to add: the thesis is fee-base compounding, not quarter-to-quarter realization upside, so entry price matters more than near-term headlines.
• Pair trade: long KKR / short a more beta-sensitive asset manager or diversified financial with weaker recurring fees over 3-6 months; the spread should work if fundraising continues while market volatility slows AUM growth elsewhere.
• Buy KKR call spreads 6-9 months out, targeting upside tied to evidence of fee-related earnings expansion; defined-risk structures fit because the stock’s re-rating path should be gradual rather than explosive.
• If credit spreads widen materially or private-market NAVs soften, trim 25-30% of the position quickly: those are the main catalysts that can compress the multiple before the 2027 fundraising cycle is fully reflected.
• Watch for quarterly fundraising and fee-related earnings inflections as the real catalyst, not adjusted EPS beats; if those inflect for two consecutive quarters, add to the position even if the headline multiple looks full.